Optimize Your In Vivo Preclinical Research

Need help optimizing your preclinical strategy? Contact Apredica now.

Until just a few years ago many drug efficacy and DMPK studies that required in vivo studies as a primary assay can now be either predicted or made more reliable by in vitro methods. In many cases the in vitro methods provide additional information about human enzymes and potential human toxicity, metabolism, and permeability that animal testing will not.

To speed drug-discovery and to reduce costs, experienced drug-discovery groups take thorough advantage of in vitro research options before engaging in in vivo research. While adding in vitro studies to a research program is an extra step, and extra steps intuitively seem to slow things down and create more costs, this extra step actually speeds up research and reduces costs. The reason for this is that relative to in vivo methods, in vitro methods are much lower cost, higher throughput, faster. And these advantages are multiplied by the fact that most preclinical research involves compounds that are never going to make it to IND. Failure is a fact of life in drug discovery. In vitro methods allow drug-discovery companies to get past their failures faster and at less cost, so they can focus their efforts on what will succeed.

Avoiding In Vivo Research Failure Outcomes

The costs and turnaround times for in vitro research are substantially less than that of in vivo research. In vitro assessment of metabolism, solubility, solubility, permeability, cytotoxicity, and pre-formulation work allows drug-discovery companies to narrow down the drug candidates that are most likely to reach the target organ or receptor in the most cost- and time-effective manner. Preceding in vivo studies by in vitro studies avoids costly, time-consuming in vivo research on compounds that will not progress towards IND.

Selecting the Optimal In Vivo CRO

Apredica’s scientists have many years of expertise in drug discovery in all major therapeutic areas. They are available to discuss with you your drug-discovery program and help you explore your preclinical research options. Apredica maintains relationships with several select in vivo contract research labs, an in vivo facility that rents fully licensed and staffed in vivo suites, and with a firm that specializes in identifying and qualifying CROs. Our scientists can help guide you to the in vivo options best suited for your research needs.

Contact Apredica now to learn more about how Apredica can help you with your discovery and preclinical research programs.